Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03639051 · ClinicalTrials.gov registry record · NA

Evaluation of the Safety and Efficacy of TLD in Patients with COPD

A NA study of COPD, sponsored by Nuvaira.

Active
Registry status
NA
Development phase
464
Enrollment target
20
Study locations

NCT03639051 is a NA study of COPD that is active but no longer recruiting, run by Nuvaira. The registered enrollment target is 464 participants, below the 2,413-participant average among 85 other COPD trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03639051, a NA study of COPD, is active but no longer recruiting, sponsored by Nuvaira.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
464 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.

Conditions Studied

Interventions

  • DEVICE Targeted Lung Denervation (TLD)
  • OTHER Optimal Medical Care

Study Locations (20)

California

  • UC Davis - Sacramento
  • Harbor UCLA - Torrance

Illinois

  • University of Chicago - Chicago
  • Suburban Lung Associates - Elk Grove Village

Michigan

  • University of Michigan - Ann Arbor
  • Spectrum Health Medical Group - Grand Rapids

North Carolina

  • Duke University - Durham
  • First Health of the Carolinas - Pinehurst

Pennsylvania

  • Temple Lung Center - Philadelphia
  • University of Pittsburgh Medical Center (UPMC) - Pittsburgh

Texas

  • St. Davids HealthCare - Georgetown
  • Houston Methodist Hospital - Houston

Alabama

  • University of Alabama at Birmingham (UAB) Lung Health Center - Birmingham

Arizona

  • HonorHealth - Phoenix

Trial Details

FieldValue
Enrollment Target 464 participants
Start Date 2019-05-23
Est. Completion 2028-09
Phase NA

Sponsor

Nuvaira

2 total trials

What the Registry Record Tells You About NCT03639051

The ClinicalTrials.gov registry entry for NCT03639051 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,413-participant average among 85 other COPD trials with a reported enrollment target (81% lower). The listed sponsor is Nuvaira, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Targeted Lung Denervation (TLD) is the first listed.

NCT03639051 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, Michigan.

Frequently Asked Questions

What is clinical trial NCT03639051 about?

NCT03639051 is a clinical study titled "Evaluation of the Safety and Efficacy of TLD in Patients with COPD". The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.

What is the current status of trial NCT03639051?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 464 participants. The study started on 2019-05-23. Estimated completion is 2028-09.

What conditions does trial NCT03639051 study?

This clinical trial studies the following conditions: COPD.

What interventions are being tested in trial NCT03639051?

The interventions under investigation include: Targeted Lung Denervation (TLD) (DEVICE), Optimal Medical Care (OTHER).

Who is sponsoring clinical trial NCT03639051?

This trial is sponsored by Nuvaira, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03639051 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.